

"Non-binary" categorical data has more than 2 values (A, B, C, \dots). We talk about this data in terms of the entire *distribution*, i.e. the probability function ($\mathbf{Prob}(A), \mathbf{Prob}(B), \mathbf{Prob}(C), \dots$). Of course we could omit one of these, since it would be implicit, but it is inconvenient.

Dagbigatran is an anticoagulant used for e.g. stroke prevention in patients with atrial fibrillation. *The following example only looks at side effects.*

718 people were randomized to Dabigatran or placebo and observed for some set time for bleeding.

id	intervention	bleeding
1	dabigatran	Yes
2	placebo	No
3	placebo	No
4	dabigatran	No
⋮	⋮	⋮
718	placebo	No


	Bleeding		Sum
	Yes	No	
dabigatran	27	320	347
placebo	8	363	371
Sum	35	683	718

Measures for dabigatran:


- **Risk** (probability of an unwanted event)
Risk of bleeding = $27/347 = 7.8\%$
- **Odds** (how much more likely it is, versus not, to experience an event)
Odds of bleeding
$$= \frac{27/347}{320/347} = \frac{27}{320} = 8.4\%$$

(Odds? Sometimes this is easier to model.)

For an event with probability p , the odds is $p/(1 - p)$.



For small probabilities: odds \approx probability.



- if an event has odds θ , then its probability p is $p = \theta/(1 + \theta)$
 $\theta = 2$ corresponds to $p = 2/3$.
 $\theta = 1$ corresponds to $p = 1/2$.
 $\theta = 1/100$ corresponds to $p = 1/101$.
- in a betting game where you stand to win 1 unit of money, your stake S (if this is kept when winning) should not exceed the odds
 - 'expected' profit $= 1 \frac{\theta}{1+\theta} - S \frac{1}{1+\theta} \geq 0$ is equivalent to $S \leq \theta$
 - If you are offered x units of money for a game you think has odds 2 (in your favor) then do not bet more than $2x$.
 Betting $2x$ makes the game "fair".
- there are multiple systems of betting (sports) 'odds', that are not odds in the sense of this course!

	Bleeding		Sum
	Yes	No	
dabigatran	27	320	347
placebo	8	363	371
Sum	35	683	718

Measures for risk of dabigatran versus placebo

- (Risk ratio (RR)) $= \frac{27/347}{8/371} \approx 3.6$
- Odds ratio (OR) $= \frac{27/320}{8/363} \approx 3.8$
- Risk difference $= 27/347 - 8/371 \approx 0.056$

The OR contains no information about the probabilities.
 If you know the 'denominator' probability (p_2) then the 'numerator' probability (p_1) can be calculated

$$p_1 = \frac{OR \cdot p_2}{1 + (OR - 1) \cdot p_2}.$$


For small values of p_2 and 'moderate' values of OR

$$p_1 \approx OR \cdot p_2.$$

Deviation (%) between approximation and exact formula:

'denominator' (p_2)	Odds Ratio (OR)				
	0.1	0.5	1	2	10
1 %	−0.9	−0.5	0	1	9
5 %	−4.5	−2.5	0	5	45
10 %	−9.0	−5.0	0	10	90
50 %	−45.0	−25.0	0	50	450

The blue dotted lines are the approximations.




	Bleeding		Sum
	Yes	No	
dabigatran	X	(347-X)	347
placebo	(35-X)	(683-347+X)	371
Sum	35	(683)	718

Suppose that whether a person bleeds or not is complete independent of intervention. (H_0 : "odds ratio = 1".)

Then the 35 individuals who bled should be a random sample of the study population (of size 718) and we would expect that $X/35 = 347/718 \approx 48\%$.

We would expect X to be 17-18, but is $X = 27$ within some acceptable range of possibilities?


Simulate (500 times) the experiment of randomly selecting 35 people from the study population and record the number who got dabigatran (15, 15, 16, 18, 16...)



However, we can calculate *exactly* what the distribution of X is *given* H_0 (in this case).

The p -value is the probability of a discrepancy the size of that between the observed and the expected.

Sum the red values to get $p = 0.00045$.



My software produced the following output:

Fisher's Exact Test for Count Data

```
data:  Dabigatran_example
p-value = 0.0004458
alternative hypothesis: true odds ratio is not equal to 1
95 percent confidence interval:
 1.659358 9.877595
sample estimates:
odds ratio
 3.821942
```

So odds ratio is between 1.7 and 9.9. (Allows for test of model.) Probabilities are small, so risk of dabigatran is (approx.) between 1.7 and 9.9 times larger than placebo risk.

Risk Ratio?

So

The odds ratio of bleeding with dabigatran versus placebo is 3.8 (1.7–9.9).

The placebo risk is $p_2 = 8/371 \approx 2.2\%$ so we can use an earlier formula to get $p_1 =$ (risk with dabigatran) and thus the RR:

OR	1.7	3.8	9.9
$p_1 =$	3.5%	7.8%	18%
RR =	1.6	3.6	8.3

So

The risk ratio of bleeding with dabigatran versus placebo is 3.6 (1.6–8.3).

(**N.B** The implied confidence interval (above) for p_1 is "too wide" since it takes to much uncertainty into account.)

Risk difference

What is the *difference* in risk between dabigatran and placebo?

This has (almost) been covered by Lars. One needs to know that for two **independent** estimators (having SE_1 and SE_2) the SE for their difference is given by

$$\sqrt{SE_1^2 + SE_2^2}.$$

Risk	Estimate	Standard error
dabigatran $p_1 = 27/347 = 0.078$	$\sqrt{p_1(1 - p_1)/347} = 0.0144$	
placebo $p_2 = 8/371 = 0.022$	$\sqrt{p_2(1 - p_2)/371} = 0.0075$	
difference $p_1 - p_2 = 0.056$	$\sqrt{0.0144^2 + 0.0075^2} = 0.0162$	

We get a 95% confidence interval for the difference with

$$(0.056 \pm 1.96 \cdot 0.0162) = (0.024, 0.088).$$

(This allows for test of model.)

Absolute risk

What can we say about the *absolut* risk of bleeding with dabigatran?

This was covered by Lars in Lecture 3! (Genotype example.)

The risk estimate $27/347 = 0.078$ has a standard error (SE) given by

$$\sqrt{\frac{0.078(1 - 0.078)}{347}} = 0.0144.$$

This yields a 95% confidence interval given by

$$(0.078 \pm 1.96 \cdot 0.0144) = (0.050, 0.11).$$

(This allows for test of model.)

Have we exhausted the Dabigatran example yet?

Summary of the dabigatran example:

Quantity	Estimate	Confidence interval
p_1	0.078	(0.050, 0.11)
$p_1 - p_2$	0.056	(0.024, 0.088)
OR (p_1 vs. p_2)	3.82	(1.7, 9.9)

Cosmetic skin testing

To prove a new product is hypoallergenic it should provoke no more skin reactions than current market leader.

To test a new product 40 individuals got both products applied to two patches of skin and observed for reaction (yes/no)

id	new	market
1	no	no
2	yes	no
3	no	no
\vdots	\vdots	\vdots
40	yes	yes

McNemars test for paired data

		new		
		no	yes	Σ
market	no	17	5	22
	yes	15	3	18
	Σ	32	8	40

McNemars test only considers the pairs where the results are different.

With new product there are 8 reactions but 3 of them would have happened anyway. The new product 'creates' 5 reactions, whereas the market leader 'creates' 15 reactions.

Switching from the market leader to the new product would benefit 15, make it worse for 5, and have no effect on 20. (In terms of skin reactions.)

A test statistic can be calculated. p -value for H_0 : 'no difference' is approx 4%.

Is the new product as good as the market leader?

The following table is *not* appropriate to answer that question.

	no	yes
old	22	18
new	32	8

The rows are dependent.

Note:

One *can* estimate (and get confidence intervals) for p_1 and p_2 (risk of skin reaction with new and old, respectively).

But it is harder to quantify the SE for risk difference and OR, due to the dependence.

Other situations

Twins being randomized to intervention or placebo:

		Placebo	
		improvement	non
Intervention	improvement	a	b
	non	c	d

Before/after data:

		Before	
		event	non
After	event	a	b
	non	c	d

References

- Chapters 23-25: Petrie & Sabin. *Medical Statistics at a Glance*, Wiley-Blackwell (2009).
- Grant, R. L.: Converting an odds ratio to a range of plausible relative risks for better communication of research findings, *BMJ* **348** (2014) 7 pages.